PPAPAlso known as: Prostatic acid phosphatase, Thiamine Monophosphatase, 5'-Nucleotidase, ACP3

Mechanism of Action

PPAP (Prostatic Acid Phosphatase) is an enzyme that functions as a phosphatase hydrolyzing phosphate esters, particularly in the prostate tissue. It dephosphorylates various substrates, impacting phosphate metabolism and contributing to physiological processes such as thiamine metabolism and nucleotidase activity. Its enzymatic activity modulates signaling pathways and cellular communication by regulating phosphate group removal from proteins and small molecules.

Reported Research Benefits

PPAP is researched primarily in prostate cancer biomarker studies, endocrinology related to prostate function, and enzyme activity assays. It serves as a target or tool in studies involving prostate tissue health, hormone regulation, and immune response related to prostate conditions. It is also used in ELISA and latex immunoturbidimetric assays for detection purposes.

Dosing Protocol & Reconstitution

As a recombinant protein used in research, dosing is dependent on application protocols such as ELISA or immunoassays. Typical recombinant protein concentrations range from nanogram to microgram amounts per assay well, tailored per experimental design. No standard in vivo dosing exists as it is for research use only.

Research Notes

PPAP has been studied extensively for its role as a biomarker in prostate cancer and other prostate diseases. Recombinant forms are used in diagnostic assay development and immunological studies. The protein exhibits enzymatic stability suitable for immunoassays but is not intended for therapeutic use. Research also highlights its involvement in thiamine metabolism and nucleotidase activity. Studies range from clinical sample analysis to in vitro enzymatic assays.

Research Summary

PPAP, or Prostatic Acid Phosphatase, has been extensively studied as a biomarker in prostate cancer and related prostate conditions. Clinical research supports its use in diagnostic assays, particularly immunological tests such as ELISA, for detecting prostate pathology. While recombinant protein variants facilitate assay development and biochemical studies, translational applications remain largely diagnostic rather than therapeutic. Most research comprises clinical sample analyses and in vitro characterizations with moderate to high quality evidence.

Side Effects & Safety

PPAP recombinant protein is intended solely for research use; there are no documented side effects from experimental assays. However, if administered inappropriately in vivo, potential immunogenic reactions could occur due to protein nature and expression in E. coli. Researchers should handle with standard laboratory safety precautions. No systemic toxicity or drug interaction data exist due to its non-therapeutic classification.

Stability & Storage

Refer to research notes

Molecular Data

Molecular Weight: 36372 g/mol

Primary literature: https://pubmed.ncbi.nlm.nih.gov/?term=PPAP